Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9614 posts found.

EMA backs plozasiran for rare lipid disorder with high pancreatitis risk

April 27, 2026 Research and Development The European Medicines Agency (EMA), plozasiran

The European Medicines Agency (EMA) has recommended granting a marketing authorisation for Redemplo (plozasiran) to treat adults with familial chylomicronaemia …
News

Study explores speech as marker in rare neurodegenerative disease

April 27, 2026 Research and Development SynaptixBio, neurodegenerative disease

SynaptixBio has highlighted the potential of speech analysis as a non-invasive way to track disease progression in neurodegenerative conditions, as …
News

Kayentis and RWS partner to improve clinical trial data confidence

April 17, 2026 Research and Development RWS, kayentis

Kayentis and RWS have announced a partnership aimed at improving confidence in clinical trial data for neuroscience and other complex …
News

MHRA expands its pioneering AI Airlock programme with £3.6m funding boost

April 16, 2026 Research and Development

The Medicines and Healthcare products Regulatory Agency (MHRA) has secured new funding to expand its AI Airlock programme, aimed at …
News

Gesynta Pharma doses first patient in endometriosis phase 2 trial

April 14, 2026 Research and Development Gesynta Pharma, endometriosis

Gesynta Pharma has dosed the first patient in its phase 2 clinical proof-of-concept trial of vipoglanstat. The trial, NOVA, is …
News

Kainova Therapeutics expands phase I/II trial of antibody drug

April 7, 2026 Research and Development

Kainova Therapeutics has announced that the first patient in the European expansion of its DOMISOL phase I/II clinical trial evaluating …
News
drug-trials

Eisai starts enrolment for phase 2 narcolepsy study evaluating E2086

April 7, 2026 Research and Development

Eisai is to begin enrolling participants in its phase 2 study, Study 202, in patients with narcolepsy. The company registered …
News

Roche adds 2,176 NVIDIA Blackwell GPUs to its hybrid-cloud AI factory

March 25, 2026 Research and Development AI, NVIDIA, Roche

Roche has expanded its global AI infrastructure with a NVIDIA AI factory, adding 2,176 high-performance graphics processing units (GPUs) across …
News

EndoCyclic New Drug application approved by US FDA for endometriosis treatment

March 24, 2026 Research and Development EndoCyclic Therapeutics, FDA, endometriosis

EndoCyclic Therapeutics’ Investigational New Drug (IND) application for its lead programme, ENDO-205, has been approved by the US FDA. With …
News

Outrun Therapeutics announces its lead programme for HPV positive cancer

March 23, 2026 Research and Development HPV, Oncology, Outrun Therapeutics

Outrun Therapeutics has selected an E6AP inhibitor strategy as its lead programme for treating HPV positive head and neck cancer. …
News

Under-Secretary of State for Health Innovation and Safety visits new building on University of Huddersfield’s NHIC

March 18, 2026 Research and Development NHS, University of Huddersfield, West Yorkshire

Dr Zubir Ahmed MP, the Under-Secretary of State for Health Innovation and Safety, has visited the recently opened Emily Siddon …
News

DiaMedica gets regulatory clearance from Health Canada for phase 2 preeclampsia study

March 11, 2026 Research and Development DiaMedica, Health Canada, preeclampsia

DiaMedica Therapeutics has received a No Objection Letter (NOL) from Health Canada, giving the company regulatory clearance to start its …
News

Abselion establishes a US subsidiary in Massachusetts 

March 10, 2026 Research and Development Abselion, The Engine, US

Abselion has established a US subsidiary at The Engine in Cambridge, Massachusetts in the US. The company aims to strengthen …
News

Antiverse receive investment from IIC and Development Bank of Wales

March 9, 2026 Research and Development Antiverse, Wales, funding

As part of its $9.3m Series A funding round, Antiverse has received a joint equity investment by Innovation Investment Capital …
News

Secarna Pharmaceuticals and Curie.Bio expand existing partnership

March 6, 2026 Research and Development Curie.Bio, Secarna Pharmaceuticals, partnership

Secarna Pharmaceuticals has announced the expansion of the existing scientific and strategic collaboration agreement with Curie.Bio. The collaboration, first announced …
News
The Gateway to Local Adoption Series

Latest content

EMA backs plozasiran for rare lipid disorder with high pancreatitis risk

April 27, 2026

Study explores speech as marker in rare neurodegenerative disease

April 27, 2026

Ofichem brings all brands under single trading name

April 23, 2026

Carvolix strengthens its Board of Directors, advisory board and governance structure

April 23, 2026

Under-Secretary of State for Health Innovation and Safety visits new building on University of Huddersfield’s NHIC

April 22, 2026